Maria Jesus Penarrubia

Maria Jesus Penarrubia

Auto-generated profile, based on publicly available information

Maria Jesus Penarrubia

Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EBEmmanuel Bachy
Emmanuel Bachy
Vincent CamusVincent Camus
Vincent Camus
CTCatherine Thieblemont
Catherine Thieblemont
DSDavid Sibon
David Sibon
RCRene Olivier Casasnovas
Rene Olivier Casasnovas
RDRichard Delarue
Richard Delarue
PURPOSE: Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Results from a phase Ib and II study showed the feasibility of combining romidepsin with CHOP (Ro-CHOP). METHODS: This study is a randomized phase III study of Ro-CHOP versus CHOP in adult patients with previously untreated PTCL. All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m2, was administered intravenously over a 4-hour period on days 1 and 8 of each 3-week cycle for six cycles. The primary end point was progression-free survival (PFS) according to International Working Group 1999 criteria. RESULTS: Between January 2013 and December 2017, 421 patients were enrolled (Ro-CHOP, n = 211; CHOP, n = 210). The median PFS for Ro-CHOP versus CHOP was 12.0 months (95% CI, 9.0 to 25.8) versus 10.2 months (95% CI, 7.4 to 13.2) with a hazard ratio of 0.81 ( P = .096). In the Ro-CHOP versus CHOP arms, the median overall survival was 51.8 versus 42.9 months and the objective response rate was 63% versus 60% with complete response plus unconfirmed complete response rates of 41% versus 37% ( P > .1 in all comparisons), respectively. Grade 3 or 4 treatment-emergent adverse events occurring in ≥ 30% of patients in the Ro-CHOP arm included thrombocytopenia (50% v 10% in the Ro-CHOP v CHOP arms, respectively), neutropenia (49% v 33%), anemia (47% v 17%), and leukopenia (32% v 20%). CONCLUSION: The addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency for grade ≥ 3 treatment-emergent adverse events. Ro-CHOP does not represent a significant advance in the standard of care for patients with previously untreated PTCL.

10 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Vincent CamusVincent Camus
Vincent Camus
CTCatherine Thieblemont
Catherine Thieblemont
PGPhilippe Gaulard
Philippe Gaulard
MCMorgane Cheminant
Morgane Cheminant
RCRene Olivier Casasnovas
Rene Olivier Casasnovas
EBEmmanuel Bachy
Emmanuel Bachy
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The primary analysis of the Ro-CHOP phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT01796002 ) established that romidepsin (Ro) plus cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) did not yield an increased efficacy compared with CHOP alone as first-line treatment of peripheral T-cell lymphoma. We report the planned final analysis 5 years after the last patient enrolled. With a median follow-up of 6 years, median progression-free survival (PFS) was 12.0 months compared with 10.2 months (hazard ratio [HR], 0.79 [95% CI, 0.62 to 1.005]; P = .054), while median overall survival was 62.2 months (35.7-86.6 months) and 43.8 months (30.1-70.2 months; HR, 0.88 [95% CI, 0.68 to 1.14]; P = .324) in the Ro-CHOP and CHOP arms, respectively. In an exploratory analysis, the median PFS in the centrally reviewed follicular helper T-cell lymphoma subgroup was significantly longer in the Ro-CHOP arm (19.5 v 10.6 months, HR, 0.703 [95% CI, 0.502 to 0.985]; P = .039). Second-line treatments were given to 251 patients with a median PFS2 and OS2 after relapse or progression of 3.3 months and 11.5 months, respectively. Within the limits of highly heterogeneous second-line treatments, no specific regimen seemed to provide superior disease control. However, a potential benefit was observed with brentuximab vedotin in association with chemotherapy even after excluding anaplastic large-cell lymphoma subtype or after adjusting for histology and international prognostic index in a multivariate model (HR for PFS, 0.431 [95% CI, 0.238 to 0.779]; P = .005).

1 January 2003 in The Hematology Journal
Verified
Journal Article
Closed access
OGOliver Gutierrez
Oliver Gutierrez
ACAlberto Cantalapiedra
Alberto Cantalapiedra
MTMaría Isabel Tabuyo
María Isabel Tabuyo
RVRosario Del Villar
Rosario Del Villar
MPMaría Jesús Peñarrubia
María Jesús Peñarrubia
LGL Javier García-Frade
L Javier García-Frade

20 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BRBeatriz Rey-Búa
Beatriz Rey-Búa
CGCarlos Grande
Carlos Grande
JBJose Javier Sánchez Blanco
Jose Javier Sánchez Blanco
PAPau Abrisqueta
Pau Abrisqueta
AGAntonio Gutierrez
Antonio Gutierrez
AMAlejandro Martín
Alejandro Martín
Purpose: This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods: The IBDCL trial (NCT02692248) included patients with histologic diagnosis of non-GCB DLBCL with relapsed or refractory disease and non-candidates for stem-cell transplantation. Patients received an induction treatment consisting of six or eight cycles of R-GemOx at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years. The primary objective was to evaluate the overall response rate after four cycles. Results: Sixty-four patients were included, 72% of them refractory to the last regimen. The overall response rate and complete remission rate after the fourth cycle were 53% [95% confidence interval (CI), 41–65] and 34% (95% CI, 24–46), respectively. Twenty-four (37%) patients started maintenance, and 7 (11%) completed the planned 2 years. After a median follow-up of 29.7 months (range: 0.4–48.6), the estimated 2-year progression-free survival and overall survival were 18% (95% CI, 8–28) and 26% (95% CI, 14–37), respectively. The most common grade ≥3 treatment-related adverse events were thrombocytopenia (44%), neutropenia (30%), and anemia (14%). Grade ≥3 infectious and cardiovascular treatment-related adverse events were reported in 6 (9%) and 1 (2%) patient, respectively. Conclusions: Ibrutinib in combination with R-GemOx, followed by ibrutinib maintenance, demonstrated encouraging antitumor activity with durable responses and a manageable toxicity in patients with non-GCB DLBCL.

1 August 2008 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
PDF file
BMB. Madrigal
B. Madrigal
JAJ. J. Arenal
J. J. Arenal
ATArmando Torres
Armando Torres
MPM. J. Peñarrubia
M. J. Peñarrubia
AVA. Vara
A. Vara
PEP. Enríquez
P. Enríquez